Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Dermata Therapeutics, Inc. - Warrant
(NQ:
DRMAW
)
0.0189
-0.0001 (-0.53%)
Streaming Delayed Price
Updated: 2:55 PM EST, Feb 25, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
364
Open
0.0171
Bid (Size)
0.0171 (15,500)
Ask (Size)
0.0188 (1,000)
Prev. Close
0.0190
Today's Range
0.0171 - 0.0189
52wk Range
0.0102 - 0.0440
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Dermata Receives Notice of Grant of Patent for Next-Generation Acne Treatment by Australian Patent Office
January 20, 2026
Via
ACCESS Newswire
Dermata Therapeutics Announces Closing of up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
December 29, 2025
Via
ACCESS Newswire
Performance
YTD
+2.2%
+2.2%
1 Month
-10.8%
-10.8%
3 Month
+2.2%
+2.2%
6 Month
-14.9%
-14.9%
1 Year
-32.5%
-32.5%
More News
Read More
Dermata Therapeutics Announces up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
December 24, 2025
Via
ACCESS Newswire
A New Realm of Skincare is Coming: Dermata Teases New OTC Brand Identity
December 04, 2025
Via
ACCESS Newswire
Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
November 14, 2025
Via
ACCESS Newswire
Dermata to Present on BioPub on January 31, 2025
January 29, 2025
Via
ACCESS Newswire
Dermata Receives Approval from FDA for the Proprietary Name Xyngari(TM)
December 16, 2024
Via
ACCESSWIRE
Dermata Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of Acne
December 10, 2024
Via
ACCESSWIRE
Dermata Announces Acceptance of Patent Application for Next-Generation Acne Treatment by Australian Patent Office
October 02, 2025
Via
ACCESS Newswire
Dermata Therapeutics Announces Presentation of Abstract at the European Academy of Dermatology and Venereology Congress 2025
September 17, 2025
Via
ACCESS Newswire
Dermata Therapeutics to Present at the Life Sciences Virtual Investor Forum September 18th
September 16, 2025
From
Virtual Investor Conferences
Via
GlobeNewswire
Dermata Therapeutics Announces Strategic Pivot to Over-the-Counter Skin Care Treatments
September 10, 2025
Via
ACCESS Newswire
Dermata Completes Enrollment in First Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne
December 03, 2024
Via
ACCESSWIRE
Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
November 13, 2024
Via
ACCESSWIRE
Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results
August 13, 2025
Via
ACCESS Newswire
Dermata Receives Notice of Grant of Australian Patent for Topical Botulinum Toxin Treatment for Hyperhidrosis
July 08, 2025
Via
ACCESS Newswire
Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
May 14, 2025
Via
ACCESS Newswire
Dermata’s XYNGARI(TM) Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks
April 15, 2025
Via
ACCESS Newswire
Dermata Therapeutics Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules
March 27, 2025
Via
ACCESS Newswire
Dermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial Results
March 17, 2025
Via
ACCESS Newswire
Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Botulinum Toxin Treatment for Hyperhidrosis
February 25, 2025
Via
ACCESS Newswire
Dermata Therapeutics Announces $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules
January 22, 2025
Via
ACCESS Newswire
Dermata and Revance Enter Clinical Trial Collaboration Agreement for the Topical Application of Xyngari(TM) with Daxxify(R)
January 21, 2025
Via
ACCESS Newswire
Dermata Therapeutics to Present at the Life Sciences Investor Forum on Thursday, November 14, 2024
November 11, 2024
From
Virtual Investor Conferences
Via
GlobeNewswire
Dermata Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit on Tuesday, October 15, 2024
October 08, 2024
Via
ACCESSWIRE
Frequently Asked Questions
Is Dermata Therapeutics, Inc. - Warrant publicly traded?
Yes, Dermata Therapeutics, Inc. - Warrant is publicly traded.
What exchange does Dermata Therapeutics, Inc. - Warrant trade on?
Dermata Therapeutics, Inc. - Warrant trades on the Nasdaq Stock Market
What is the ticker symbol for Dermata Therapeutics, Inc. - Warrant?
The ticker symbol for Dermata Therapeutics, Inc. - Warrant is DRMAW on the Nasdaq Stock Market
What is the current price of Dermata Therapeutics, Inc. - Warrant?
The current price of Dermata Therapeutics, Inc. - Warrant is 0.0189
When was Dermata Therapeutics, Inc. - Warrant last traded?
The last trade of Dermata Therapeutics, Inc. - Warrant was at 02/25/26 02:55 PM ET
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
